1. Jernigan JA, Stephens DS, Ashford DA, et al: Bioterrorism related inhalational anthrax: The first 10 cases reported in the United States.
Emerg Infect Dis 7:933, 2001.
[PubMed: 11747719]
2. Tucker JB: Historical trends related to bioterrorism: An empirical analysis.
Emerg Infect Dis 5:498, 1999.
[PubMed: 10458952]
3. Health Aspects of Chemical and Biological Weapons: Report of a WHO Group of Consultants. Geneva, World Health Organization, 1970, pp 72, 99.
4. Inglesby TV, Grossman R, O'Toole T: A plague on your city: Observations from TOPOFF.
Clin Infect Dis 32:436, 2001.
[PubMed: 11170952]
5. O'Toole T: Smallpox: An attack scenario.
Emerg Infect Dis 5:540, 1999.
[PubMed: 16550536]
6. Rotz LD, Khan AS, Lillibridge SR, et al: Public health assessment of potential biological terrorism agents.
Emerging Infect Dis 8:225, 2002.
[PubMed: 11897082]
7. Khan AS, Sage MJ: The Centers for Disease Control's Strategic Planning Workgroup, Biological and chemical terrorism: Strategic plan for preparedness and response. Morb Mortal Wkly Rep 49(RR-4):1, 2000.
10. Birerzvige A: Inhalation Hazard from Reaerosolized Biological Agents: a Review [report No. CRDEC-TR-413]. Aberdeen Proving Ground, MD: Chemical Research Development and Engineering Center, 1992.
11. Chinn KSK: Aerosol Penetration of Chemical Protective Overgarment [report No. DPG/JCP-94/005]. Dugway, UT: Joint Contact Point Directorate, U.S. Army Dugway Proving Ground, 1994.
12. Morrow PE, Yu CP: Models of Aerosol Behavior in Airways. Aerosols in Medicine: Principles, Diagnosis and Therapy. New York, Elsevier Science Publishers (Biomedical Division), 1985, p 149.
13. Sobel J, Khan AS, Swerdlow DL: Threat of a biological terrorist attack on the US food supply: The CDC perspective.
Lancet 359:874, 2002.
[PubMed: 11897303]
14. Inglesby TV, Henderson DA, Bartlett JG, et al: Anthrax as a biological weapon: Medical and public health management.
JAMA 281:1735, 1999.
[PubMed: 10328075]
15. Dixon
TC, Meselson M, Guillemin J, et al: Anthrax.
N Engl J Med 341:815, 1999.
[PubMed: 10477781]
16. Meselson M, Guillemin J, Hugh-Jones M, et al: The Sverdlosk anthrax outbreak of 1979.
Science 266:1202, 1994.
[PubMed: 7973702]
17. Friedlander A, Welkos SL, Pitt ML, et al: Postexposure prophylaxis against experimental inhalation anthrax,
J Infect Dis 167:1239, 1993.
[PubMed: 8486963]
18. Brossier F, Mock M: Toxins of
Bacillus anthracis.
Toxicon 39:1747, 2001.
[PubMed: 11595637]
20. Dahlgren CM, Buchanan LM, Decker HM, et al:
Bacillus anthracis aerosols in goat hair processing mills.
Am J Hyg 72:24, 1960.
[PubMed: 13813720]
21. Walker JS, Lincoln RE, Klein F: Pathophysiological and biochemical changes in anthrax.
Fed Proc 26:1539, 1967.
[PubMed: 4963768]
22. Amramova FA, Grinberg LM, Yampolskaya O, et al: Pathology of inhalational anthrax in 42 cases from the Sverdlovsk outbreak in 1979. Proc Natl Acad Sci USA 90:2291, 1993.
23. Kim HJ, Jun WB, Lee SH, et al: CT and MRI findings of anthrax meningoencephalitis: Report of two cases and review of the literature.
Am Soc Neuroradiol 22:1303, 2001.
[PubMed: 11498418]
24. Franz DR, Jahrling PB, Friedlander A, et al: Clinical recognition and management of patients exposed to biological warfare agents.
JAMA 278:399, 1997.
[PubMed: 9244332]
25. Mayer TA, Matcha SB, Murphy C: Clinical presentation of inhalational anthrax following bioterrorism exposure: Report of 2 surviving patients.
JAMA 286:2549, 2001.
[PubMed: 11722268]
26. Vessal K, Yeganehdoust J, Dutz W, Kohout E: Radiologic changes in inhalation anthrax.
Clin Radiol 26:471, 1975.
[PubMed: 811421]
27. Barnes JM: Penicillin and B anthracis. J Pathol Bacteriol 194:113, 1947.
28. Lincoln RE, Klein F, Walker JS, et al: Successful treatment of monkeys for septicemic anthrax, in Antimicrobial Agents and Chemotherapy—1964. Washington, American Society for Microbiology, 1965, p 759.
29. Penn C, Klotz SA: Anthrax, in Gorbach SL, Bartlett JG, Blacklow NR (eds): Infectious Diseases. Philadelphia, WB Saunders, 1998, p 1575.
30. Knisely RF: Selective medium for
Bacillus anthracis.
J Bacteriol 92:784, 1966.
[PubMed: 4958778]
31. Miller JM: Agents of bioterrorism: Preparing for bioterrorism at the community health care level.
Infect Dis Clin 15:1127, 2001.
[PubMed: 11780270]
32. Swartz MN: Recognition and management of anthrax—an update.
N Engl J Med 345:1621, 2001.
[PubMed: 11704686]
33. CDC guidelines for state health departments on how to handle anthrax and other biological agent threats (revised Oct. 14, 2001). Atlanta, Centers for Disease Control and Prevention.
http://www.bt.cdc.gov. Accessed October 26, 2001.
35. Inglesby TV, Dennis DT, Henderson DA, et al: Plague as a biological weapon: Medical and public health management.
JAMA 283:2281, 2000.
[PubMed: 10807389]
36. Centers for Disease Control and Prevention: Human plague—United States, 1993–1994. Morb Mortal Wkly Rep 43:242, 1994.
37. Butler T: Yesinia species (including plague), in Mandell GL, Bennett JE, Dolin R (eds): Principles and Practice of Infectious Diseases. New York, Churchill Livingstone, 1995, p 2070.
38. Centers for Disease Control and Prevention: Fatal human plague. Morb Mortal Wkly Rep 278:380, 1997.
39. Freidlander AM, McGovern TW: Plague, in Sidell FR, Takafuji ET, Franz DR (eds): Part I: Medical Aspects of Chemical and Biological Warfare (Textbook of Military Medicine). Office of the Surgeon General, Department of the Army, United States of America, 1997, p 479.
41. Reyn CF, Weber NS, Tempest B, et al: Epidemiologic and clinical features of an outbreak of bubonic plague in New Mexico. J Infect Dis 136:489, 1977.
42. Dennis JA, Mettler FA, Mann JM: Radiographic manifestations of plague in New Mexico, 1975–1980. Radiology 139:561, 1981.
43. Dennis JC, Vernalo JR, Lombardi LJ, et al: Plague pneumonia: Disease caused by Yesinia pestis. Semin Respir Med 12:12, 1997.
44. Florman AL, Spencer RR, Sheward S: Multiple lung cavities in a 12 year old girl with bubonic plague, sepsis, and secondary pneumonia.
Am J Med 80:1191, 1986.
[PubMed: 3728514]
45. Hull H, Montes JM, Mann JM: Septicemic plague in New Mexico.
J Infect Dis 155:113, 1987.
[PubMed: 3794395]
46. Werner SB, Weidmer CE, Nelson BC, et al: Primary plague pneumonia contracted from a domestic cat in South Lake Tahoe, California.
JAMA 251:929, 1984.
[PubMed: 6694294]
47. Centers for Disease Control and Prevention: Pneumonic plague—Arizona. Morb Mortal Wkly Rep 41:737, 1992.
49. Centers for Disease Control and Prevention: Prevention of plague: Recommendations of the Advisory Committee on Immunization Practices. Morb Mortal Wkly Rep 45:RR-14, 1996.
50. Cross JT, Penn RL: Francisella tularensis tularemia, in Mandell GL, et al (eds): Principles and Practice of Infectious Diseases. Philadelphia, Churchill Livingstone, 2000, p 2393.
51. Saslaw S, Eigelsbach HT, Prior JA, et al: Tularemia vaccine study. II: Respiratory challenge. Arch Intern Med 107:134, 1961.
52. Geyer SJ, Burkey A, Chandler FW: Tularemia, in Connor DH (ed): Pathology of Infectious Diseases. Stamford, CT, Appleton & Lange, 1997, p 869.
53. Evans ME, Gregory DW, Schaffner W, McGee ZA: Tularemia: a 30-year experience with 88 cases.
Medicine 64:251, 1985.
[PubMed: 3892222]
54. Freidlander AM, Evans ME: Tularemia, in Sidell FR, Takafuji ET, Franz DR (eds): Part I: Medical Aspects of Chemical and Biological Warfare (Textbook of Military Medicine). Office of the Surgeon General, Department of the Army, United States of America, 1997, p 503.
55. Cunha BA, Gill V: Tularemia pneumonia.
Semin Respir Infect 12:61, 1997.
[PubMed: 9097380]
56. Sunderrajan EV, Hutton J, Marienfeld D: Adult respiratory distress syndrome secondary to tularemia pneumonia.
Arch Intern Med 145:1435, 1985.
[PubMed: 4026475]
58. Overholt EL, Tigert WD, Kadull PJ, et al: An analysis of forty two cases of laboratory acquired tularemia.
Am J Med 30:785, 1961.
[PubMed: 13731776]
59. Franz DR, Pitt LM, Clayton MA, et al: Efficacy of prophylactic and therapeutic administration of antitoxin for inhalation botulism, in DasGupta BR (ed): Botulinum and Tetanus Neurotoxins: Neurotransmission and Biomedical Aspects. New York, Plenum Press, 1993, p 473.
60. Pettersson T, Nyberg P, Nordstrom D, et al: Similar pleural fluid in pleuropulmonary tularemia and tuberculous pleurisy.
Chest 109:572, 1996.
[PubMed: 8620743]
61. Dennis DT, Inglesby TV, Henderson DA: Tularemia as a biological weapon: Medical and public health management.
JAMA 285:2763, 2001.
[PubMed: 11386933]
62. Shapiro RL, Hatheway C, Swerdlow DL: Botulism in the United States: a clinical and epidemiologic review.
Ann Intern Med 129:221, 1998.
[PubMed: 9696731]
64. Gangarosa EJ, Donadio JA, Armstrong RW, et al: Botulism in the United States, 1899–1969.
Am J Epidemiol 93:93, 1971.
[PubMed: 4925448]
65. Mann JM, Martin S, Hoffman R, Marrazzo S: Patient recovery from type A botulism: Morbidity assessment following a large outbreak.
Am J Public Health 71:266, 1981.
[PubMed: 7468858]
66. MontecuccoC (ed): Clostridial neurotoxins: The molecular pathogenesis of tetanus and botulism. Curr Top Microbiol Immunol 195:1, 1995.
68. Hughes JM, Blumenthal JR, Merson MH, et al: Clinical features of types A and B food-borne botulism.
Ann Intern Med 95:442, 1981.
[PubMed: 7283294]
69. Nowara WWS, Samet JM, Rosario PA: Early and late pulmonary complications of botulism. Arch Intern Med 143:451, 1983.
70. Cherington M: Clinical spectrum of botulism.
Muscle Nerve 21:701, 1998.
[PubMed: 9585323]
71. Khajehdehi P: Toxemic shock, hematuria, hypokalemia, and hypoproteinemia in a case of cutaneous anthrax.
Mt Sinai J Med 68:213, 2001.
[PubMed: 11373695]
72. Santos JI, Swensen P, Glasgow LA: Potentiation of
Clostridium botulinum toxin by aminoglycoside antibiotics: Clinical and laboratory observations.
Pediatrics 68:50, 1981.
[PubMed: 7243509]
74. Arnon SS, Schecter R, Inglesby TV: Botulinum toxin as a biological weapon: Medical and public health management.
JAMA 285:1059, 2001.
[PubMed: 11209178]
75. World Health Organization: The Global Eradication of Smallpox: Final Report of the Global Commission for the Certification of Smallpox Eradication. Geneva, World Health Organization, 1980, p 5. Available at
http://whqlibdoc.who.int/publications/a41438.pdf. Accessed February 2002.
76. Mcclain DJ: Smallpox, in Sidell FR, Takafuji ET, Franz DR (eds): Part I: Medical Aspects of Chemical and Biological Warfare (Textbook of Military Medicine). Office of the Surgeon General, Department of the Army, United States of America, 1997, p 539.
77. Fenner F, Henderson DA, Arita I, et al: Smallpox and its eradication. Geneva, World Health Organization, 1988, p 1460.
78. Breman JG, Henderson DA: Diagnosis and management of smallpox.
N Engl J Med 346:1300, 2002.
[PubMed: 11923491]
79. Koplan JP, Foster SO: Smallpox: Clinical types, causes of death, and treatment.
J Infect Dis 140:440, 1979.
[PubMed: 501158]
80. Esposito JJ, Massung RF: Poxvirus infections in humans, in Murray PR, Tenover F, Baron EJ (eds): Clinical Microbiology. Washington, American Society of Microbiology, 1995, p 1131.
81. Henderson DA, Inglesby TV, Bartlett JG, et al: Smallpox as a biological weapon: Medical and public health management.
JAMA 281:2127, 1999.
[PubMed: 10367824]
82. Meltzer MI, Damon I, LeDuc JW, et al: Modeling potential responses to smallpox as a bioterrorist weapon.
Emerg Infect Dis 7:959, 2001.
[PubMed: 11747722]
83. Frey SE, Couch RB, Tacket CO, et al: Clinical responses to undiluted and diluted smallpox vaccine.
N Engl J Med 346:1265, 2002.
[PubMed: 11923490]
84. Centers for Disease Control: Vaccinia (smallpox) vaccine recommendations of the Advisory Committee on Immunization Practices (ACIP), 2001. Morb Mortal Wkly Rep 50(RR-10):1, 2001.
85. Centers of Disease Control: Notice to readers update: Management of patients with suspected viral hemorrhagic fever–United States. Morb Mortal Wkly Rep 44:475, 1995.
86. Jahrling PB: Viral hemorrhagic fevers, in Sidell FR, Takafuji ET, Franz DR (eds): Part I: Medical Aspects of Chemical and Biological Warfare (Textbook of Military Medicine). Office of the Surgeon General, Department of the Army, United States of America, 1997, p 591.
87. McCormick JB, King IJ, Webb PA, et al: A case-control study of the clinical diagnosis and course of Lassa fever.
J Infect Dis 155:445, 1987.
[PubMed: 3805772]
88. PetersCJ: Arenaviridae and bunyaviridae, in Mandell GL, Bennett JE, Dolin R (eds): Principles and Practice of Infectious Diseases. New York, Churchill Livingstone, 1995, p 1856.
89. Bwaka MA, Bonnet MJ, Calain P, et al: Ebola hemorrhagic fever in Kikwit, Democratic Republic of the Congo: Clinical observations in 103 patients. J Infect Dis 179(Suppl 1):S1, 1999.
90. Heyman DL, Barakamfitye D, Szczeniowski M, et al: Ebola hemorrhagic fever: Lessons learned from Kikwit, Democratic Republic of the Congo. J Infect Dis 179(Suppl 1):S283, 1999.
91. Soni A, Chugh K, Sachdev A, et al: Management of dengue in ICU.
Indian J Pediatr 68:1051, 2001.
[PubMed: 11770241]
92. Hallin G, Simpson S, Cromwell R, et al: Cardiopulmonary manifestations of hantavirus pulmonary syndrome.
Crit Care Med 24:252, 1996.
[PubMed: 8605797]
94. Ulrich RG, Sheldon S, Taylor T, et al: Staphylococcal enterotoxin B and related pyrogenic toxins, in Sidell FR, Takafuji ET, Franz DR (eds): Part I: Medical Aspects of Chemical and Biological Warfare (Textbook of Military Medicine). Office of the Surgeon General, Department of the Army, United States of America, 1997, p 621.
95. Smith JF, Davis KY, Hart MK, et al: Viral encephalitides, in Sidell FR, Takafuji ET, Franz DR (eds): Part I: Medical Aspects of Chemical and Biological Warfare (Textbook of Military Medicine). Office of the Surgeon General, Department of the Army, United States of America, 1997, p 561.
96. Wilhelmsen C, Pitt L: Lesions of acute inhaled lethal ricin intoxication in rhesus monkeys. Vet Pathol 30:482, 1993.
97. Roccaforte JD, Cushman JG: Disaster preparation and management for the intensive care unit.
Curr Opin Crit Care 8:607, 2002.
[PubMed: 12454550]
99. Simon R, Teperman S: The World Trade Center Attack. Lessons for disaster management.
Crit Care 5:318, 2001.
[PubMed: 11737917]
100. Borio L, Frank D, Mani V, et al. Death due to bioterrorism-related inhalational anthrax: Report of 2 patients.
JAMA 286:2554, 2001.
[PubMed: 11722269]
101. Downie A, Dumbell K: Survival of variola virus in dried exudates and crusts in small pox patients. Lancet 1:550, 1947.
102. Bartlett J, Borio L, Radonovich L, et al: Small pox vaccination in 2003: Key information for clinicians.
Clin Infect Dis 36:883, 2003.
[PubMed: 12652390]